The AVENIO Tumor Profiling Kits are a portfolio of NGS assays that enable in-house targeted profiling or comprehensive genomic profiling (CGP) for clinical research. Through an integrated end-to-end workflow, AVENIO Kits offer a versatile solution to evaluate solid tumors from DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue or plasma samples (FFPE samples only for CGP).
Designed to match the content of the 324-gene FoundationOne® CDx panel, the assay detects four classes of genomic alterations as well as genomic signatures: TMB, MSI, LOH.
A 17 gene (81kb) pan-cancer assay that contains guideline-aligned biomarkers, including those identified by the U.S. National Comprehensive Cancer Network (NCCN).2
A 77 gene (192kb) pan-cancer assay that contains 17 genes in the NCCN and other guidelines, plus 60 emerging biomarkers investigated in clinical research.
A 17 gene (81kb) pan-cancer assay containing genes in NCCN guidelines and optimized for lung cancer and colorectal cancer research.
A 77 gene (192kb) pan-cancer assay containing genes in the NCCN guidelines and emerging biomarkers, and optimized for lung cancer and colorectal cancer research.